Cardiomyopathy

The PBS subsidises mavacamten for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), and tafamidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with mavacamten under the National Health Act 1953, section 85 for adult patients with symptomatic obstructive HCM.

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with tafamidis under the National Health Act 1953, section 85 for patients with ATTR-CM.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing mavacamten and tafamidis.

Treatment specifics

To be eligible for PBS-subsidised treatment with mavacamten, patients must be treated by either a:

  • cardiologist
  • consultant physician with experience in the management of HCM.

To be eligible for PBS-subsidised treatment with tafamidis, patients must be treated by and the authority application completed by, either a:

  • cardiologist
  • consultant physician with experience in the management of amyloid disorders.

Authority applications

Mavacamten

Applying for initial treatment

Apply for initial authority approval to prescribe PBS-subsidised mavacamten to treat symptomatic obstructive HCM in writing and either:

All written applications must include:

Applying for initial grandfather treatment

For patients who received non-PBS-subsidised mavacamten treatment before 1 May 2024 for symptomatic obstructive HCM, apply for initial grandfather authority approval in writing and either:

All written applications must include:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised mavacamten to treat symptomatic obstructive HCM can be made either:

Tafamidis

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised tafamidis to treat ATTR-CM can be made either in:

All written applications must include:

Applying for initial grandfather treatment

Applications for initial grandfather authority approval to prescribe PBS-subsidised tafamidis to treat ATTR-CM can be made either in:

All written applications must include:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised tafamidis to treat ATTR-CM can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 18 June 2024.
QC 65884